Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differentiation of diffuse idiopathic skeletal hyperostosis (DISH) with back pain from back pain without DISH-clinical hints.

EULAR rheumatology open·2026
Same author

Whole Spine and Sacroiliac Joint MRI of Patients With and Without Metabolic Syndrome: A Preliminary Study.

Diagnostics (Basel, Switzerland)·2026
Same author

The Presence of Diffuse Idiopathic Skeletal Hyperostosis (DISH) among Patients with High Burden of Cardiovascular Risk Factors: A Retrospective Study.

International journal of rheumatology·2025
Same author

Association Between Vascular Calcifications on Joint Radiographs and Calcium Pyrophosphate Crystal Arthritis: A Medical Records Review Study.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2025
Same author

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.

RMD open·2024
Same author

Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.

Journal of clinical pharmacology·2024

Related Experiment Video

Updated: Jul 10, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Optimizing treatment with biologics.

Reuven Mader1, Edward Keystone

  • 1Rebecca McDonald Centre for Arthritis and Autoimmune Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

The Journal of Rheumatology. Supplement
|November 7, 2007
PubMed
Summary
This summary is machine-generated.

Early, aggressive treatment with biologic agents, often combined with methotrexate, can significantly improve outcomes for rheumatoid arthritis (RA) by controlling disease activity and preventing joint damage.

Related Experiment Videos

Last Updated: Jul 10, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) causes rapid disability and joint damage early in the disease course.
  • Disease activity is the primary driver of early RA disability, while irreversible joint damage contributes later.
  • Conventional disease-modifying antirheumatic drugs (DMARDs) and combination therapies have been used to control RA.

Purpose of the Study:

  • To review strategies for managing rheumatoid arthritis (RA) using biologic agents.
  • To explore the efficacy of early and aggressive therapeutic interventions in RA management.
  • To assess the impact of novel treatment strategies on disease control and joint preservation.

Main Methods:

  • Review of recent therapeutic strategies for RA management.
  • Analysis of combination therapies involving conventional DMARDs and biologic agents.
  • Evaluation of early biologic administration, alone or with methotrexate, for RA treatment.

Main Results:

  • Biologic agents offer new strategies, including early monotherapy or combination with methotrexate.
  • Biologics can be used for moderate RA or for inducing remission followed by conventional DMARDs.
  • Aggressive, early therapy with close monitoring and strategy modification yields improved outcomes.

Conclusions:

  • Early and aggressive treatment, particularly with biologics, is crucial for optimal RA management.
  • Biologic therapies, when initiated early and monitored closely, can significantly improve patient outcomes.
  • Tight control strategies with targeted outcomes enhance disease management irrespective of the specific treatment approach.